サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405878

抗生物質の市場規模、シェア、動向分析レポート：作用機序別、薬剤クラス別、タイプ別、セグメント予測、2024年～2030年

Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 145 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.42円
抗生物質の市場規模、シェア、動向分析レポート：作用機序別、薬剤クラス別、タイプ別、セグメント予測、2024年～2030年
出版日: 2023年12月19日
発行: Grand View Research
ページ情報: 英文 145 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗生物質市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗生物質市場規模は2024年から2030年にかけて4.2%のCAGRを記録し、2030年までに680億3,000万米ドルに達すると予測されています。

高い需要、抗生物質耐性プログラムへの注目の高まり、抗生物質の誤用を避けるための取り組み、ジェネリック医薬品の容易な入手が市場成長の要因となっています。抗生物質の購入プロセスは主に医師の影響を受ける。複数のジェネリック医薬品が入手可能なため、購入者は簡単に切り替えることができます。医療機関向けビジネスの場合、価格割引が選択手順において重要な役割を果たします。これにより、市場関係者の利益率はさらに低下します。しかし、ブランド品や特許製品では、買い手にはこうした特権はないです。

さらに、規制当局はフルオロキノロンの使用を制限するガイドラインを発表しています。したがって、予測期間中、買い手の交渉力は低いと予想されます。State of World's Antibiotics（世界の抗生物質事情）」レポートによると、2021年、インドにおける抗菌薬使用量は全体で30％急増します。さらに、CDCの米国における抗生物質の使用状況レポート（2021年最新版）によると、米国の小売薬局では約2,500万件の処方箋が調剤されています。その中で、アジスロマイシンは2021年に処方された主要な製剤でした。このように、抗菌薬の消費パターンの増加は、予測期間中の市場成長を促進すると思われます。新製品の承認と上市は市場の成長をサポートすると予想されます。

例えば、2020年6月、米国FDAは、人工呼吸器関連細菌性肺炎および院内細菌性肺炎の治療薬として、シラスタチン-イミペネムとレリバクタムの配合剤であるRecarbrioの承認を発表しました。同製品は2019年7月、腹腔内感染症および尿路感染症（UTI）の適応で初めて承認されました。今後数年間は、Generating Antibiotics Incentives Now Act、Global Research on Antimicrobial Resistance（GRAM）Project、Global Antibiotic Research &Development Partnership（GARDP）などの政府施策が市場の成長を牽引すると予測されます。さらに、これらの組織は、最先端の先端医薬品の開発プロセスを推進し、抗生物質医薬品の承認プロセスを円滑化すると期待されています。

抗生物質市場レポートハイライト

  • 新しく開発された抗生物質の商業的成功が乏しいため、政府・非政府機関は抗菌薬の研究開発活動にインセンティブを与えるために特定の戦略を実施しました。
  • 例えば、BARDAとの政府提携は、感染症に対する新規治療法の研究開発活動を促進するために様々な企業を支援しています。BARDAはAstraZenecaやGSK plcのような複数の製薬会社と提携しています。
  • 細胞壁合成阻害剤セグメントは、グラム陽性菌とグラム陰性菌に対する幅広い活性スペクトルのため、2023年に最大のシェアを占めました。
  • RNA合成阻害剤セグメントは、製品上市と研究開発イニシアチブの急増により、2024年から2030年にかけて最も速いCAGRを記録すると予想されています。
  • ジェネリックタイプのセグメントは、ジェネリック製剤の手頃な価格とジェネリック医薬品を採用する政府の取り組みにより、2023年に最大のシェアを占めました。
  • 2023年にはペニシリン薬剤クラス別セグメントが市場を牽引しました。しかし、セファロスポリン薬セグメントは2024年から2030年にかけて最も速いCAGRを記録すると予測されています。
  • アジア太平洋地域は、大手企業による投資の増加やジェネリック抗生物質の採用率の高さから、予測期間中に最も速いCAGRを示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗生物質市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 抗生物質市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗生物質市場：薬剤クラスの推定・動向分析

  • 薬剤クラスの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 薬剤クラス別の世界の抗生物質市場の見通し
  • 以下の市場規模、予測および動向分析、2018年から2030年まで
    • セファロスポリン
    • ペニシリン
    • フルオロキノロン
    • マクロライド系
    • カルバペネム類
    • アミノグリコシド
    • スルホンアミド
    • 7-ACA
    • その他

第5章 抗生物質市場：タイプの推定・動向分析

  • タイプ市場シェア、2023年および2030年
  • セグメントダッシュボード
  • タイプ別の世界の抗生物質市場の見通し
  • 以下の市場規模、予測および動向分析、2018年から2030年まで
    • ブランド抗生物質
    • ジェネリック抗生物質

第6章 抗生物質市場：作用機序の推定・動向分析

  • 作用機序の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 作用機序別の世界の抗生物質市場の見通し
  • 以下の市場規模、予測および動向分析、2018年から2030年まで
    • 細胞壁合成阻害剤
    • タンパク質合成阻害剤
    • DNA合成阻害剤
    • RNA合成阻害剤
    • ミコール酸阻害剤
    • その他

第7章 抗生物質市場：地域の推定・動向分析

  • 地域市場シェア分析、2023年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • 主要ディストリビューターとチャネルパートナーのリスト
    • 主要顧客
    • 主要企業シェア分析、2023年
    • AbbVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck &Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Viatris, Inc.
    • Melinta Therapeutics LLC
    • Cipla, Inc.
    • Shionogi &Co., Ltd.
    • KYORIN Pharmaceutical Co., Ltd.
    • GSK plc
    • Nabriva Therapeutics PLC
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 9 Canada Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 12 Europe Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 16 Germany Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Germany Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 19 UK Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 UK Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 22 France Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 25 Italy Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Italy Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 28 Spain Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Spain Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 31 Denmark Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Denmark Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 34 Sweden Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Sweden Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 37 Norway Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Norway Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 44 China Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 47 Japan Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Japan Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 50 India Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 India Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 53 South Korea Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Korea Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 56 Australia Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Australia Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 59 Thailand Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Thailand Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 62 Latin America Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 66 Brazil Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Brazil Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 69 Mexico Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 Mexico Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 72 Argentina Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Argentina Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 75 MEA Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 MEA Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 79 South Africa Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 South Africa Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 85 UAE Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 UAE Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotics market: market outlook
  • Fig. 14 Antibiotics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotics market driver impact
  • Fig. 20 Antibiotics market restraint impact
  • Fig. 21 Antibiotics market strategic initiatives analysis
  • Fig. 22 Antibiotics market: Drug Class movement analysis
  • Fig. 23 Antibiotics market: Drug Class outlook and key takeaways
  • Fig. 24 Cephalosporin market estimates and forecast, 2018 - 2030
  • Fig. 25 Penicillin market estimates and forecast, 2018 - 2030
  • Fig. 26 Fluoroquinolone market estimates and forecast, 2018 - 2030
  • Fig. 27 Macrolides market estimates and forecast, 2018 - 2030
  • Fig. 28 Carbapenems market estimates and forecast, 2018 - 2030
  • Fig. 29 Aminoglycosides market estimates and forecast, 2018 - 2030
  • Fig. 30 Sulfonamides market estimates and forecast, 2018 - 2030
  • Fig. 31 7-ACA market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Antibiotics Market: Type movement Analysis
  • Fig. 34 Antibiotics market: Type outlook and key takeaways
  • Fig. 35 Branded Antibiotics market estimates and forecasts, 2018 - 2030
  • Fig. 36 Generic Antibiotics market estimates and forecasts,2018 - 2030
  • Fig. 37 Antibiotics market: Action Mechanism movement analysis
  • Fig. 38 Antibiotics market: Action Mechanism outlook and key takeaways
  • Fig. 39 Cell Wall Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 40 Protein Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 41 DNA Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 42 RNA Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 43 Mycolic Acid Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030
  • Fig. 45 Global Antibiotics market: Regional movement analysis
  • Fig. 46 Global Antibiotics market: Regional outlook and key takeaways
  • Fig. 47 Global Antibiotics market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America: SWOT
  • Fig. 54 Europe SWOT
  • Fig. 55 Asia Pacific SWOT
  • Fig. 56 Latin America SWOT
  • Fig. 57 MEA SWOT
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2018 - 2030
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 65 Europe
  • Fig. 66 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 67 UK
  • Fig. 68 UK market estimates and forecasts, 2018 - 2030
  • Fig. 69 Germany
  • Fig. 70 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 71 France
  • Fig. 72 France market estimates and forecasts, 2018 - 2030
  • Fig. 73 Italy
  • Fig. 74 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 75 Spain
  • Fig. 76 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 77 Denmark
  • Fig. 78 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 79 Sweden
  • Fig. 80 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 81 Norway
  • Fig. 82 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 83 Asia Pacific
  • Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 85 China
  • Fig. 86 China market estimates and forecasts, 2018 - 2030
  • Fig. 87 Japan
  • Fig. 88 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 89 India
  • Fig. 90 India market estimates and forecasts, 2018 - 2030
  • Fig. 91 Thailand
  • Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Korea
  • Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 Latin America
  • Fig. 98 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 99 Brazil
  • Fig. 100 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 101 Mexico
  • Fig. 102 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 105 Middle East and Africa
  • Fig. 106 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 107 South Africa
  • Fig. 108 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 Saudi Arabia
  • Fig. 110 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 111 UAE
  • Fig. 112 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 113 Kuwait
  • Fig. 114 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 115 Market share of key market players- Antibiotics market
目次
Product Code: GVR-1-68038-149-8

Antibiotics Market Growth & Trends:

The global antibiotics market size is expected to reach USD 68.03 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. High demand, increasing focus on antibiotic resistance programs, initiatives undertaken to avoid the misuse of antibiotics, and easy availability of generic drugs are responsible for market growth. The purchasing process of antibiotics is primarily influenced by physicians. The availability of multiple generic products provides buyers with easy switching options. In the case of institutional businesses, price discounts play an important role in the selection procedure. This can further reduce the profit margins of market players. However, buyers do not have these privileges in branded or patented products.

Furthermore, regulatory authorities have issued the guidelines for limited use of fluoroquinolones. Hence, the bargaining power of buyers is anticipated to be low over the forecast period. According to the State of World's Antibiotics report, in 2021, the overall antimicrobial drug usage in India has increased sharply by 30%. Moreover, according to the CDC's Antibiotics Usage in United States report, 2021 update, around 25 million prescriptions were dispensed from U.S. retail pharmacies. Among them, azithromycin was the leading formulation prescribed in 2021. Thus, the rising consumption pattern of antibacterial drugs is likely to fuel the market growth during the projected period. New product approvals and launches are expected to support market growth.

For instance, in June 2020, the U.S. FDA announced the approval of Recarbrio, a combination of cilastatin-imipenem and relebactam, for the treatment of ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia. The product was first approved for intra-abdominal infections and Urinary Tract Infections (UTIs) in July 2019. In the upcoming years, market growth is projected to be driven by governmental measures, such as the Generating Antibiotics Incentives Now Act, Global Research on Antimicrobial Resistance (GRAM) Project, and the Global Antibiotic Research & Development Partnership (GARDP). Moreover, these organizations are expected to propel the process of developing cutting-edge advanced medications and smoothen the approval process of antibiotic drugs.

Antibiotics Market Report Highlights:

  • Owing to the dearth of commercial success of newly developed antibiotics, government & non-government bodies implemented certain strategies to incentivize antibacterial drug R&D activities
  • For instance, the government alliance with BARDA is supporting various companies to facilitate R&D activities in novel therapies for infectious diseases. BARDA has been associated with several pharmaceutical companies like AstraZeneca and GSK plc
  • The cell wall synthesis inhibitor segment held the largest share in 2023 owing to its wide spectrum of activity against gram-positive and gram-negative bacteria
  • The RNA synthesis inhibitors segment is anticipated to register the fastest CAGR from 2024 to 2030 due to a surge in product launches and R&D initiatives
  • The generic type segment held the largest share in 2023 due to the affordability of generic formulations and government initiatives to adopt generic drugs
  • The penicillin drug class segment led the market in 2023. However, the cephalosporin segment is anticipated to register the fastest CAGR from 2024 to 2030
  • Asia Pacific is expected to exhibit the fastest CAGR over the forecast period due to the rising investments by leading players and the high adoption of generic antibiotics in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Action Mechanism
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Type
    • 2.2.3. Action Mechanism
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Development of advanced products
      • 3.2.1.2. Increasing prevalence of infectious diseases
      • 3.2.1.3. Growing collaborations for development of antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High number of patent expirations
      • 3.2.2.2. High R&D cost
  • 3.3. Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Cephalosporin
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Penicillin
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Fluoroquinolone
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Macrolides
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Carbapenems
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Aminoglycosides
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Sulfonamides
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.8. 7-ACA
      • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Branded Antibiotics
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Generic Antibiotics
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 6.1. Action Mechanism Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotics Market by Action Mechanism Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cell Wall Synthesis Inhibitors
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Protein Synthesis Inhibitors
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. DNA Synthesis Inhibitors
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. RNA Synthesis Inhibitors
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Mycolic Acid Inhibitors
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lupin Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Viatris, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Melinta Therapeutics LLC
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Cipla, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shionogi & Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. KYORIN Pharmaceutical Co., Ltd.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GSK plc
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Nabriva Therapeutics PLC
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives